|February 21, 2017VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid CancerTEL AVIV, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today full results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer. The data will be presented today by Dror Harats, M.D., CEO of VBL Therapeutics, at the Federation of the Is|
|February 06, 2017VBL Therapeutics to Present at the 2017 BIO CEO & Investor ConferenceTEL AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the BIO CEO & Investor Conference, being held on February 13-14,|
|January 31, 2017VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology TargetTEL AVIV, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper, entitled, "Identification of Motile Sperm Domain–Containing Protein 2 as Regulator of Human Monocyte Migration" by Mendel et al., is published online|
|January 09, 2017VBL Therapeutics Provides Year End 2016 Corporate UpdateTEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017.
Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to launch a Phase 3 trial of VB-111 in Ovarian Cancer during the second half of 2017.
Interim analysis in the GL|
|January 06, 2017VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE StudyCompany Reiterates Guidance for GLOBE Interim Analysis to Occur in Mid-2017 and Final Analysis in Early 2018
TEL AVIV, Israel, Jan. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that it has completed enrollment in the GLOBE Phase 3 study evaluating the efficacy of its lead candidate ofranergene obadenovec (VB-111) |